Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma

Abstract Head and neck squamous cell carcinoma (HNSCC) is an often highly invasive tumor, infiltrating functionally important tissue areas. Achieving complete tumor resection and preserving functionally relevant tissue structures depends on precise identification of tumor-free resection margins duri...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Julia Odenthal, Mark Rijpkema, Desirée Bos, Esther Wagena, Huib Croes, Reidar Grenman, Otto Boerman, Robert Takes, Peter Friedl
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5321e473c5864bbd8857687f41fc9e44
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5321e473c5864bbd8857687f41fc9e44
record_format	dspace
spelling	oai:doaj.org-article:5321e473c5864bbd8857687f41fc9e442021-12-02T15:08:54ZTargeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma10.1038/s41598-018-28059-92045-2322https://doaj.org/article/5321e473c5864bbd8857687f41fc9e442018-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-28059-9https://doaj.org/toc/2045-2322Abstract Head and neck squamous cell carcinoma (HNSCC) is an often highly invasive tumor, infiltrating functionally important tissue areas. Achieving complete tumor resection and preserving functionally relevant tissue structures depends on precise identification of tumor-free resection margins during surgery. Fluorescence-guided surgery (FGS), by intraoperative detection of tumor cells using a fluorescent tracer, may guide surgical excision and identify tumor-positive resection margins. Using a literature survey on potential surface molecules followed by immunohistochemical validation, we identified CD44 variant 6 (CD44v6) as a constitutively expressed antigen in the invasion zone of HNSCC lesions. The monoclonal anti-CD44v6 antibody BIWA was labeled with both a near-infrared fluorescent dye (IRDye800CW) and a radioactive label (Indium-111) and dual-modality imaging was applied in a locally invasive tumor mouse model. BIWA accurately detected human HNSCC xenografts in mice with a tumor uptake of 54 ± 11% ID/g and invasion regions with an accuracy of 94%. When dissected under clinical-like conditions, tumor remnants approximately 0.7 mm in diameter consisting of a few thousand cells were identified by fluorescence imaging, resulting in reliable dissection of invasive microregions. These data indicate that CD44v6 is a suitable target for reliable near-infrared detection and FGS of invasive HNSCC lesions in vivo.Julia OdenthalMark RijpkemaDesirée BosEsther WagenaHuib CroesReidar GrenmanOtto BoermanRobert TakesPeter FriedlNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Julia Odenthal Mark Rijpkema Desirée Bos Esther Wagena Huib Croes Reidar Grenman Otto Boerman Robert Takes Peter Friedl Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma
description	Abstract Head and neck squamous cell carcinoma (HNSCC) is an often highly invasive tumor, infiltrating functionally important tissue areas. Achieving complete tumor resection and preserving functionally relevant tissue structures depends on precise identification of tumor-free resection margins during surgery. Fluorescence-guided surgery (FGS), by intraoperative detection of tumor cells using a fluorescent tracer, may guide surgical excision and identify tumor-positive resection margins. Using a literature survey on potential surface molecules followed by immunohistochemical validation, we identified CD44 variant 6 (CD44v6) as a constitutively expressed antigen in the invasion zone of HNSCC lesions. The monoclonal anti-CD44v6 antibody BIWA was labeled with both a near-infrared fluorescent dye (IRDye800CW) and a radioactive label (Indium-111) and dual-modality imaging was applied in a locally invasive tumor mouse model. BIWA accurately detected human HNSCC xenografts in mice with a tumor uptake of 54 ± 11% ID/g and invasion regions with an accuracy of 94%. When dissected under clinical-like conditions, tumor remnants approximately 0.7 mm in diameter consisting of a few thousand cells were identified by fluorescence imaging, resulting in reliable dissection of invasive microregions. These data indicate that CD44v6 is a suitable target for reliable near-infrared detection and FGS of invasive HNSCC lesions in vivo.
format	article
author	Julia Odenthal Mark Rijpkema Desirée Bos Esther Wagena Huib Croes Reidar Grenman Otto Boerman Robert Takes Peter Friedl
author_facet	Julia Odenthal Mark Rijpkema Desirée Bos Esther Wagena Huib Croes Reidar Grenman Otto Boerman Robert Takes Peter Friedl
author_sort	Julia Odenthal
title	Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma
title_short	Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma
title_full	Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma
title_fullStr	Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma
title_full_unstemmed	Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma
title_sort	targeting cd44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/5321e473c5864bbd8857687f41fc9e44
work_keys_str_mv	AT juliaodenthal targetingcd44v6forfluorescenceguidedsurgeryinheadandnecksquamouscellcarcinoma AT markrijpkema targetingcd44v6forfluorescenceguidedsurgeryinheadandnecksquamouscellcarcinoma AT desireebos targetingcd44v6forfluorescenceguidedsurgeryinheadandnecksquamouscellcarcinoma AT estherwagena targetingcd44v6forfluorescenceguidedsurgeryinheadandnecksquamouscellcarcinoma AT huibcroes targetingcd44v6forfluorescenceguidedsurgeryinheadandnecksquamouscellcarcinoma AT reidargrenman targetingcd44v6forfluorescenceguidedsurgeryinheadandnecksquamouscellcarcinoma AT ottoboerman targetingcd44v6forfluorescenceguidedsurgeryinheadandnecksquamouscellcarcinoma AT roberttakes targetingcd44v6forfluorescenceguidedsurgeryinheadandnecksquamouscellcarcinoma AT peterfriedl targetingcd44v6forfluorescenceguidedsurgeryinheadandnecksquamouscellcarcinoma
_version_	1718387997504700416

Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma

Ejemplares similares